PF-Atlas › Clinical Trials › NCT00043342

Study of Interferon Gamma-1b by Injection for the Treatment of Patients With Cystic Fibrosis

interferon gamma-1b · Phase 1

Registry ID
NCT00043342
Phase
Phase 1
Status
Completed
Drug / intervention
interferon gamma-1b
Sponsor
InterMune
Start
2002-04
Enrollment
51

About this trial

The purpose of this research study is to evaluate the safety, tolerability, and efficacy of Interferon gamma-1b (IFN-gamma 1b) when administered by subcutaneous injection over a period of 4 weeks to patients with mild-to-moderate cystic fibrosis. Additionally, preliminary assessments on the effects of IFN-gamma 1b on lung function and other indicators of health will be made.

View NCT00043342 on ClinicalTrials.gov →

Explore related

All interferon gamma-1b trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT00043342 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.